Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale.

Jan DürigJens UhligAnke GerhardtMarkus RitterGunnar HapkeJörg HeßlingPeter StaibFrieder WolffKatja KrummLudwig Fischer von Weikersthal

Published in: Cancer medicine (2022)

The results confirmed the effectiveness and safety of rituximab SC in both the FL and the DLBCL group. Satisfaction of patients and nurses with SC administration was high.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
end stage renal disease
newly diagnosed
ejection fraction
healthcare
peritoneal dialysis
patient reported outcomes
patient reported